{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:36:56Z","timestamp":1792291016730,"version":"4.4.0"},"reference-count":187,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.bbrc.2023.149130","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T19:10:14Z","timestamp":1697915414000},"page":"149130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Therapeutic targeting of angiopoietins in tumor angiogenesis and cancer development"],"prefix":"10.1016","volume":"687","author":[{"given":"Komal","family":"Thapa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heena","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagandeep","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2979-1590","authenticated-orcid":false,"given":"Thakur Gurjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2023.149130_bib1","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","article-title":"Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti-and pro-angiogenic therapies","volume":"2","author":"Shibuya","year":"2011","journal-title":"Genes & Cancer"},{"key":"10.1016\/j.bbrc.2023.149130_bib2","first-page":"58","article-title":"Pharmacological modulation of Sonic Hedgehog signaling pathways in Angiogenesis: a mechanistic perspective","volume":"504","author":"Mannan","year":"2023","journal-title":"Dev. Biochem."},{"key":"10.1016\/j.bbrc.2023.149130_bib3","article-title":"Understanding mechanistic aspect of the therapeutic role of herbal agents on neuroplasticity in cerebral ischemic-reperfusion injury","author":"Bangar","year":"2023","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bbrc.2023.149130_bib4","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.2174\/138945010791591395","article-title":"Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy","volume":"11","author":"Niu","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bbrc.2023.149130_bib5","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: beyond discovery and development","volume":"176","author":"Apte","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2023.149130_bib6","series-title":"Vascular Endothelial Growth Factor Inhibitor-Induced Hypertension: Basics for Primary Care Providers","author":"Escalante","year":"2011"},{"key":"10.1016\/j.bbrc.2023.149130_bib7","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1172\/JCI70212","article-title":"Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer","volume":"123","author":"Welti","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrc.2023.149130_bib8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","article-title":"\u2018 Vascular events\u2019toxicities with VEGF inhibitor therapies\u2013focus on hypertension and arterial thrombotic","volume":"12","author":"Touyz","year":"2018","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.bbrc.2023.149130_bib9","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbrc.2023.149130_bib10","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","article-title":"Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and . of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2","volume":"126","author":"Gheblawi","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.bbrc.2023.149130_bib11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1083\/jcb.200811159","article-title":"VE-PTP controls blood vessel development by balancing Tie-2 activity","volume":"185","author":"Inderlich","year":"2009","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbrc.2023.149130_bib12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bone.2015.11.011","article-title":"Tissue engineering strategies for promoting vascularized bone regeneration","volume":"83","author":"Almubarak","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bbrc.2023.149130_bib13","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1073\/pnas.1919764117","article-title":"Combining microenvironment normalization strategies to improve cancer immunotherapy","volume":"117","author":"Mpekris","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2023.149130_bib15","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2303740120","article-title":"KRAS mutation-driven angiopoietin 2 bestows anti-VEGF resistance in epithelial carcinomas","volume":"120","author":"Hosaka","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2023.149130_bib16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1126\/science.277.5322.48","article-title":"Signaling vascular morphogenesis and maintenance","volume":"277","author":"Hanahan","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2023.149130_bib17","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1172\/JCI84871","article-title":"Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation","volume":"126","author":"Kim","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrc.2023.149130_bib18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3390\/cells8050471","article-title":"Role of angiopoietin-2 in vascular physiology and pathophysiology","volume":"8","author":"Akwii","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bbrc.2023.149130_bib19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/0008-5472.CAN-12-2064","article-title":"Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition","volume":"73","author":"Daly","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2023.149130_bib20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3390\/cells9020457","article-title":"Role of angiopoietins in development of cancer and neoplasia associated with viral infection","volume":"9","author":"Yu","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bbrc.2023.149130_bib21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10456-009-9147-3","article-title":"The role of the Angiopoietins in vascular morphogenesis","volume":"12","author":"Thomas","year":"2009","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bbrc.2023.149130_bib22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/jbmr.2828","article-title":"Targeting VEGF and its receptors for the treatment of osteoarthritis and associated pain","volume":"31","author":"Hamilton","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bbrc.2023.149130_bib23","doi-asserted-by":"crossref","first-page":"a006478","DOI":"10.1101\/cshperspect.a006478","article-title":"\u03b1V integrins in angiogenesis and cance'r","volume":"1","author":"Weis","year":"2011","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.bbrc.2023.149130_bib24","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2023.149130_bib25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2001","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2023.149130_bib26","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1073\/pnas.1616166114","article-title":"Structural basis of Tie2 activation and Tie2\/Tie1 heterodimerization","volume":"114","author":"Leppanen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2023.149130_bib27","first-page":"105","article-title":"Nanotechnology: a new approach for ocular drug delivery system","volume":"4","author":"Mudgil","year":"2012","journal-title":"Int. J. Pharm. Pharmaceut. Sci."},{"key":"10.1016\/j.bbrc.2023.149130_bib28","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006650","article-title":"The complex role of angiopoietin-2 in the angiopoietin\u2013tie signaling pathway","volume":"2","author":"Thurston","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.bbrc.2023.149130_bib29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.irbm.2019.06.001","article-title":"\u2018Recent trends in computer assisted diagnosis (CAD) system for breast cancer diagnosis using histopathological images","volume":"40","author":"Kaushal","year":"2019","journal-title":"Irbm"},{"key":"10.1016\/j.bbrc.2023.149130_bib30","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.yexcr.2013.03.011","article-title":"Angiopoietin signaling in the vasculature","volume":"319","author":"Eklund","year":"2013","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bbrc.2023.149130_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108902","article-title":"Intervention of neuroinflammation in the traumatic brain injury trajectory: in vivo and clinical approaches","volume":"108","author":"Prabhakar","year":"2022","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.bbrc.2023.149130_bib32","doi-asserted-by":"crossref","first-page":"22445","DOI":"10.1074\/jbc.M410367200","article-title":"Effects of protein and gene transfer of the angiopoietin-1 fibrinogen-like receptor-binding domain on endothelial and vessel organization","volume":"280","author":"Weber","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2023.149130_bib33","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1104\/pp.006684","article-title":"Role of the arginyl-glycyl-aspartic motif in the action of Ptr ToxA produced by Pyrenophora tritici-repentis","volume":"130","author":"Meinhardt","year":"2002","journal-title":"Plant Physiol."},{"key":"10.1016\/j.bbrc.2023.149130_bib34","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev.cellbio.12.1.697","article-title":"RGD and other recognition sequences for integrins","volume":"12","author":"Ruoslahti","year":"1996","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.bbrc.2023.149130_bib35","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3389\/fimmu.2019.01078","article-title":"Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment","author":"Harjunpaa","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2023.149130_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0065-230X(09)02002-8","article-title":"PI3K\/PTEN signaling in angiogenesis and tumorigenesis","volume":"1","author":"Jiang","year":"2009","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.149130_bib37","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/965271","article-title":"Regulation of angiogenic functions by angiopoietins through calcium-dependent signaling pathways","author":"Pafumi","year":"2015","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.bbrc.2023.149130_bib38","first-page":"1","article-title":"Vitamin D as therapeutic modulator in cerebrovascular diseases: a mechanistic perspectives","author":"Rihal","year":"2022","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"10.1016\/j.bbrc.2023.149130_bib39","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1177\/0271678X16658301","article-title":"Autocrine release of angiopoietin-2 mediates cerebrovascular disintegration in Moyamoya disease","volume":"37","author":"Blecharz","year":"2017","journal-title":"J. Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.bbrc.2023.149130_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102486","article-title":"Systemic lupus erythematosus, endothelial progenitor cells and intracellular Ca2+ signaling: a novel approach for an old disease","volume":"112","author":"Komici","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.bbrc.2023.149130_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174021","article-title":"Angiopoietin inhibitors: a review on targeting tumor angiogenesis","volume":"899","author":"Parmar","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2023.149130_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2005821","article-title":"Genome-wide functional analyses of plant coiled\u2013coil NLR-type pathogen receptors reveal essential roles of their N-terminal domain in oligomerization, networking, and immunity","volume":"16","author":"Wroblewski","year":"2018","journal-title":"PLoS Biol."},{"key":"10.1016\/j.bbrc.2023.149130_bib43","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11912-009-0017-3","article-title":"Angiopoietin-2: development of inhibitors for cancer therapy","volume":"11","author":"Hu","year":"2009","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.bbrc.2023.149130_bib44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/biomedicines5020034","article-title":"The role of angiogenesis in cancer treatment","volume":"5","author":"Rajabi","year":"2017","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbrc.2023.149130_bib45","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1161\/ATVBAHA.119.313021","article-title":"Weibel-palade bodies orchestrate pericytes during angiogenesis","volume":"39","author":"Cossutta","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbrc.2023.149130_bib46","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.devcel.2013.08.020","article-title":"VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity","volume":"26","author":"Giannotta","year":"2013","journal-title":"Dev. Cell"},{"key":"10.1016\/j.bbrc.2023.149130_bib47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.devcel.2007.10.019","article-title":"Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia","volume":"14","author":"Gavard","year":"2008","journal-title":"Dev. Cell"},{"key":"10.1016\/j.bbrc.2023.149130_bib48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrm2639","article-title":"Control of vascular morphogenesis and homeostasis through the angiopoietin\u2013Tie system","volume":"10","author":"Augustin","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbrc.2023.149130_bib49","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1016\/j.celrep.2019.11.036","article-title":"Sphingosine-1-phosphate receptor 1 activity promotes tumor growth by amplifying VEGF-VEGFR2 angiogenic signaling","volume":"29","author":"Ragunathrao","year":"2009","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbrc.2023.149130_bib50","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1158\/0008-5472.CAN-09-1977","article-title":"Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth","volume":"70","author":"Hashizume","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2023.149130_bib51","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1073\/pnas.1525360113","article-title":"Ang-2\/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival","volume":"113","author":"Kloepper","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2023.149130_bib52","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2174\/1570161115666170713094319","article-title":"Potential role of natural compound as anti-angiogenic agents in cancer","volume":"15","author":"Shanmugam","year":"2017","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"12","key":"10.1016\/j.bbrc.2023.149130_bib53","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.3390\/pharmaceutics14122721","article-title":"Biosimilars in oncology: latest trends and regulatory status","volume":"14","author":"Joshi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbrc.2023.149130_bib54","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.jvir.2010.08.009","article-title":"Angiogenesis and current antiangiogenic strategies for the treatment of cancer","volume":"21","author":"Oklu","year":"2010","journal-title":"J. Vasc. Intervent. Radiol."},{"key":"10.1016\/j.bbrc.2023.149130_bib55","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12079-016-0352-8","article-title":"VEGF-A\/VEGFR2 signaling network in endothelial cells relevant to angiogenesis","volume":"10","author":"Abhinand","year":"2016","journal-title":"J Cell Commun Signal"},{"key":"10.1016\/j.bbrc.2023.149130_bib56","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0002-9440(10)65733-1","article-title":"Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis","volume":"153","author":"Stratmann","year":"1998","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.bbrc.2023.149130_bib57","first-page":"1287","article-title":"Significant correlation between interleukin 10 expression and vascularization through angiopoietin\/TIE2 networks in non-small cell lung cancer","volume":"7","author":"Hatanaka","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.149130_bib58","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1172\/JCI4891","article-title":"Biological significance of angiopoietin-2 expression in human hepatocellular carcinoma","volume":"103","author":"Tanaka","year":"1999","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrc.2023.149130_bib59","first-page":"2145","article-title":"Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases","volume":"61","author":"Etoh","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2023.149130_bib60","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/S0002-9440(10)65088-2","article-title":"Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma","volume":"156","author":"Brown","year":"2000","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.bbrc.2023.149130_bib61","first-page":"1900","article-title":"High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas","author":"Eggert","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.149130_bib62","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0002-9440(10)65515-0","article-title":"Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features","volume":"155","author":"Bunone","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbrc.2023.149130_bib63","first-page":"166","article-title":"Exciting new advances in neuro\u2010oncology: the avenue to a cure for malignant glioma","volume":"60","author":"Van Meir","year":"2010","journal-title":"Ca - Cancer J. Clin."},{"key":"10.1016\/j.bbrc.2023.149130_bib64","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/01.MP.0000071841.17900.69","article-title":"Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma","volume":"16","author":"Moon","year":"2003","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbrc.2023.149130_bib65","first-page":"1255","article-title":"The effects of angiopoietin-1 and-2 on tumor growth and angiogenesis in human colon cancer","volume":"61","author":"Ahmad","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2023.149130_bib66","doi-asserted-by":"crossref","first-page":"C352","DOI":"10.1152\/ajpcell.00050.2005","article-title":"Transcriptional and post-transcriptional regulation of angiopoietin-2 expression mediated by IGF and PDGF in vascular smooth muscle cells","volume":"290","author":"Phelps","year":"2006","journal-title":"Am. J. Physiol.: Cell Physiol."},{"key":"10.1016\/j.bbrc.2023.149130_bib67","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1172\/JCI0214105","article-title":"Microtumor growth initiates angiogenic with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2","volume":"109","author":"Ajkoczy","year":"2009","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrc.2023.149130_bib68","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.freeradbiomed.2011.11.002","article-title":"Role of reactive oxygen and nitrogen species in the vascular responses to inflammation","volume":"52","author":"Kvietys","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bbrc.2023.149130_bib69","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0002-9440(10)63998-3","article-title":"Angiopoietin-2 is implicated in the regulation of tumor angiogenesis","volume":"158","author":"Yu","year":"2001","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbrc.2023.149130_bib70","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.cr.7290176","article-title":"The enigmatic role of angiopoietin-1 in tumor angiogenesis","volume":"13","author":"Metheny-Barlow","year":"2003","journal-title":"Cell Res."},{"key":"10.1016\/j.bbrc.2023.149130_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2013.09.019","article-title":"The role of monocytes in angiogenesis and atherosclerosis","volume":"63","author":"Jaipersad","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bbrc.2023.149130_bib72","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1006\/exnr.1999.7162","article-title":"In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis","volume":"159","author":"Zagzag","year":"1999","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbrc.2023.149130_bib73","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1750-3639.2005.tb00115.x","article-title":"Angiogenesis in gliomas: biology and molecular pathophysiology","volume":"15","author":"Fischer","year":"2005","journal-title":"Brain Pathol."},{"key":"10.1016\/j.bbrc.2023.149130_bib74","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ajpath.2012.06.030","article-title":"Mechanisms of glioma-associated neovascularization","volume":"181","author":"Hardee","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbrc.2023.149130_bib75","series-title":"Pro-inflammatory and Angiogenic Activities of VEGF and Angiopoietins in Murine sponge\/Matrigel Model","author":"Sinnathamby","year":"2015"},{"key":"10.1016\/j.bbrc.2023.149130_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/path.1618","article-title":"Angiopoietins in tumours: the angiogenic switch","volume":"204","author":"Tait","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbrc.2023.149130_bib77","series-title":"The Interplay between Hypoxia (HIF) and Inflammation (NF-\u03ba B) in Colon Cancer (Doctoral Dissertation","author":"Bartnicka","year":"2014"},{"key":"10.1016\/j.bbrc.2023.149130_bib78","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/ng1855","article-title":"Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster","volume":"38","author":"Dews","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbrc.2023.149130_bib79","first-page":"918","article-title":"Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodeling","volume":"7","author":"Currie","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.149130_bib80","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/vhrm.2006.2.3.213","article-title":"Angiogenesis in cancer","volume":"2","author":"Nishida","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.bbrc.2023.149130_bib81","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1054\/bjoc.2000.1437","article-title":"Expression and function of angiopoietin-1 in breast cancer","volume":"83","author":"Hayes","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2023.149130_bib82","first-page":"525","article-title":"Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1\/2, thrombospondin-1 and clinicopathological significance","volume":"15","author":"Tang","year":"2006","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbrc.2023.149130_bib83","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000087840","article-title":"Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients","volume":"69","author":"Yonenaga","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.bbrc.2023.149130_bib84","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/mc.10126","article-title":"Modulation of the angiogenesis response through Ha\u2010ras control, placenta growth factor, and angiopoietin expression in mouse skin carcinogenesis","volume":"37","author":"Larcher","year":"2003","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.bbrc.2023.149130_bib85","first-page":"171","article-title":"Involvement of angiopoietins in cancer progression in association with cancer cell-fibroblast interaction","volume":"25","author":"Maruyama","year":"2005","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbrc.2023.149130_bib86","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1040-8428(00)00062-7","article-title":"Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis","volume":"34","author":"Gerwins","year":"2000","journal-title":"Crit. Rev. Oncol.-Hematol."},{"key":"10.1016\/j.bbrc.2023.149130_bib87","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/j.1365-2133.2010.09940.x","article-title":"Angiopoietin\u20101, angiopoietin\u20102 and Tie\u20102 receptor expression in human dermal wound repair and scarring","volume":"163","author":"Staton","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.bbrc.2023.149130_bib88","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0092-8674(00)81814-0","article-title":"Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2","volume":"87","author":"Vikkula","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2023.149130_bib89","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1126\/science.277.5322.55","article-title":"Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis","volume":"277","author":"Maisonpierre","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2023.149130_bib90","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.celrep.2015.08.024","article-title":"The orphan receptor Tie1 controls angiogenesis and vascular remodeling by differentially regulating Tie2 in tip and stalk cells","volume":"12","author":"Savant","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbrc.2023.149130_bib91","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.molcel.2010.02.007","article-title":"Tie1-Tie2 interactions mediate functional differences between angiopoietin ligands","volume":"37","author":"Seegar","year":"2010","journal-title":"Mol. Cell."},{"key":"10.1016\/j.bbrc.2023.149130_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms16106","article-title":"Pericyte-expressed Tie2 controls angiogenesis and vessel maturation","volume":"8","author":"Teichert","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2023.149130_bib93","first-page":"222","article-title":"Angiogenesis inhibitors: current strategies and future prospects","volume":"60","author":"Cook","year":"2010","journal-title":"Ca - Cancer J. Clin."},{"key":"10.1016\/j.bbrc.2023.149130_bib94","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/humupd\/dmr008","article-title":"\u2018GnRH agonist for triggering of final oocyte maturation\u2019: time for a change of practice?","volume":"17","author":"Humaidan","year":"2011","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.bbrc.2023.149130_bib95","first-page":"447","article-title":"Signaling pathways induced by vascular endothelial growth factor","volume":"5","author":"Larrivee","year":"2000","journal-title":"Int J Mol"},{"key":"10.1016\/j.bbrc.2023.149130_bib96","doi-asserted-by":"crossref","first-page":"a009159","DOI":"10.1101\/cshperspect.a009159","article-title":"Eph receptor signaling and ephrins","volume":"5","author":"Lisabeth","year":"2013","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.bbrc.2023.149130_bib97","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/excr.2001.5295","article-title":"Rho family GTPases regulate VEGF-stimulated endothelial cell motility","volume":"269","author":"Soga","year":"2001","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bbrc.2023.149130_bib98","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00441-014-1812-1","article-title":"Phosphatases and kinases as regulators of the endothelial barrier function","volume":"355","author":"Kuppers","year":"2014","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.bbrc.2023.149130_bib99","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ccell.2016.10.018","article-title":"Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment","volume":"30","author":"Park","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2023.149130_bib100","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0002-9440(10)65079-1","article-title":"Hypoxia-inducible angiopoietin-2 expression is mimicked by iodonium compounds and occurs in the rat brain and skin in response to systemic hypoxia and tissue","volume":"156","author":"Mandriota","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbrc.2023.149130_bib101","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00259-002-1096-7","article-title":"[18F] FMISO and [18F] FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression","volume":"30","author":"Rajendran","year":"2003","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.bbrc.2023.149130_bib102","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbrc.2023.149130_bib103","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.2353\/ajpath.2010.100059","article-title":"Angiopoietin-2-driven vascular remodeling in airway inflammation","volume":"117","author":"Tabruyn","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"8","key":"10.1016\/j.bbrc.2023.149130_bib104","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/ajh.21745","article-title":"Pericytes and vessel maturation during tumor angiogenesis and metastasis","volume":"85","author":"Raza","year":"2010","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bbrc.2023.149130_bib105","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s00262-020-02616-6","article-title":"Pro-tumorigenic functions of macrophages at the primary, invasive and metastatic tumor site","volume":"69","author":"Nasrollahzadeh","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbrc.2023.149130_bib106","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/path.2517","article-title":"Mechanisms of lymphatic metastasis in human colorectal adenocarcinoma","volume":"217","author":"Royston","year":"2009","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbrc.2023.149130_bib107","first-page":"507","article-title":"Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2","volume":"6","author":"Oliner","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2023.149130_bib108","doi-asserted-by":"crossref","DOI":"10.12659\/AOT.919414","article-title":"Recipient hepatic tumor-associated immunologic infiltrates predict outcomes after liver transplantation for hepatocellular carcinoma","volume":"25","author":"Atanasov","year":"2020","journal-title":"Ann. Transplant."},{"key":"10.1016\/j.bbrc.2023.149130_bib109","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ccr.2011.02.005","article-title":"Targeting the ANG2\/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells","volume":"19","author":"Mazzieri","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2023.149130_bib110","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.pharmthera.2016.06.001","article-title":"Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents","volume":"164","author":"Falcon","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbrc.2023.149130_bib111","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/jmri.10072","article-title":"Dynamic contrast\u2010enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti\u2010angiogenic therapy in a xenograft model of glioblastoma multiforme","volume":"15","author":"Gossmann","year":"2002","journal-title":"J. Magn. Reson. Imag."},{"key":"10.1016\/j.bbrc.2023.149130_bib112","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.critrevonc.2015.02.001","article-title":"Advances in anti-angiogenic agents for ovarian cancer treatment: the role of trebananib (AMG 386).\u2019","volume":"94","author":"Marchetti","year":"2015","journal-title":"Crit. Rev. Oncol.-Hematol."},{"key":"10.1016\/j.bbrc.2023.149130_bib113","first-page":"1923","article-title":"Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells","volume":"20","author":"Cassinelli","year":"2013","journal-title":"Comput. Mater. Continua (CMC)"},{"key":"10.1016\/j.bbrc.2023.149130_bib114","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.3390\/molecules24183259","article-title":"Design and synthesis of benzimidazole-chalcone derivatives as potential anticancer agents","volume":"24","author":"Hsieh","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bbrc.2023.149130_bib115","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nri2171","article-title":"Evolving functions of endothelial cells in inflammation","volume":"7","author":"Pober","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2023.149130_bib116","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1582-4934.2008.00254.x","article-title":"Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease","volume":"12","author":"Makinde","year":"2008","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.bbrc.2023.149130_bib117","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0065-230X(09)02002-8","article-title":"PI3K\/PTEN signaling in angiogenesis and tumorigenesis","volume":"102","author":"Jiang","year":"2009","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.149130_bib118","doi-asserted-by":"crossref","first-page":"H1862","DOI":"10.1152\/ajpheart.00651.2005","article-title":"Activation of Nrf2\/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression","volume":"290","author":"Chen","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.bbrc.2023.149130_bib119","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1242\/jcs.115.1.175","article-title":"Angiopoietin 2 stimulates migration and tube-like structure formation of murine brain capillary endothelial cells through c-Fes and c-Fyn","volume":"115","author":"Mochizuki","year":"2002","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bbrc.2023.149130_bib120","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1091\/mbc.e02-01-0006","article-title":"Rac regulates endothelial morphogenesis and capillary assembly","volume":"13","author":"Connolly","year":"2002","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.bbrc.2023.149130_bib121","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1160\/TH09-06-0403","article-title":"Driving Rho GTPase activity in endothelial cells regulates barrier integrity","volume":"103","author":"Beckers","year":"2010","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.bbrc.2023.149130_bib122","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.molmed.2020.11.006","article-title":"Permeability of the endothelial barrier: identifying and reconciling controversies","volume":"27","author":"Claesson-Welsh","year":"2021","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bbrc.2023.149130_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.954645","article-title":"The adipose tissue microenvironment in cancer: molecular mechanisms and targets for treatment","volume":"10","author":"Yang","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bbrc.2023.149130_bib124","first-page":"1","article-title":"Targeting the ER\u03b2\/Angiopoietin-2\/Tie-2 signaling-mediated angiogenesis with the FDA-approved anti-estrogen Faslodex to increase the Sunitinib sensitivity in RCC","volume":"1","author":"Gu","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbrc.2023.149130_bib125","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(14)70244-X","article-title":"Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"Monk","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2023.149130_bib126","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000187794","article-title":"Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency","volume":"66","author":"Chatelut","year":"1994","journal-title":"Nephron"},{"key":"10.1016\/j.bbrc.2023.149130_bib127","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.critrevonc.2015.10.006","article-title":"Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; in the light of completed trials","volume":"98","author":"Korkmaz","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bbrc.2023.149130_bib128","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/cncr.31172","article-title":"Phase 2 and biomarker study of trebananib, an angiopoietin\u2010blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma","volume":"124","author":"Reardon","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2023.149130_bib129","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/annonc\/mds502","article-title":"Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer","volume":"224","author":"Eatock","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbrc.2023.149130_bib130","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2023.149130_bib131","doi-asserted-by":"crossref","DOI":"10.1097\/IGC.0000000000000891","article-title":"Paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma","volume":"27","author":"Rose","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.bbrc.2023.149130_bib132","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.bbrc.2023.149130_bib133","first-page":"167","article-title":"A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. Clin. Genitourin","volume":"12","author":"Hong","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2023.149130_bib134","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3233\/KCA-180041","volume":"3","author":"Semrad","year":"2019","journal-title":"Kidney Cancer"},{"key":"10.1016\/j.bbrc.2023.149130_bib135","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0026","article-title":"Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism","volume":"9","author":"Karagiannis","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbrc.2023.149130_bib136","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3324\/haematol.2016.152710","article-title":"Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia","volume":"102","author":"Cortes","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.bbrc.2023.149130_bib137","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/1535-7163.TARG-19-B055","article-title":"Phase 1b\/2 study of rebastinib (DCC-2036) in combination with paclitaxel: preliminary safety, efficacy, pharmacokinetics, and pharmacodynamics in patients with advanced or metastatic solid tumors","volume":"18","author":"Janku","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.bbrc.2023.149130_bib138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-019-0771-9","article-title":"Angiopoietin-1 and angiopoietin-2 inhibitors: clinical development","volume":"21","author":"Gillen","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.bbrc.2023.149130_bib139","first-page":"1321","article-title":"MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models","volume":"40","author":"Leow","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbrc.2023.149130_bib140","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ygyno.2017.12.029","article-title":"Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies","volume":"148","author":"Gray","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbrc.2023.149130_bib141","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/cac2.12183","article-title":"Improving antitumor immunity using antiangiogenic agents: mechanistic insights, current progress, and clinical challenges","volume":"41","author":"Li","year":"2021","journal-title":"Cancer Commun."},{"key":"10.1016\/j.bbrc.2023.149130_bib142","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-15-2145","article-title":"A phase I, first-in-human study of AMG 780, an angiopoietin-1 and-2 inhibitor, in patients with advanced solid tumors","volume":"22","author":"Dowlati","year":"2016","journal-title":"Clin Cancer"},{"key":"10.1016\/j.bbrc.2023.149130_bib143","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(17)30239-5","article-title":"Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial","volume":"18","author":"Heery","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2023.149130_bib144","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/bjc.2012.594","article-title":"A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma","volume":"108","author":"Peeters","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2023.149130_bib145","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1158\/1078-0432.CCR-17-1588","article-title":"First-in-human phase I study of single-agent vanucizumab, a first-in-class bispecific anti-angiopoietin-2\/anti-VEGF-A antibody, in adult patients with advanced solid tumors","volume":"24","author":"Hidalgo","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.149130_bib146","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1517\/13543784.2013.793306","article-title":"Targeting angiopoietin-2 signaling in cancer therapy","volume":"22","author":"Eroglu","year":"2013","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.bbrc.2023.149130_bib147","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2165\/00002018-200932090-00003","article-title":"Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer","volume":"32","author":"Theou-Anton","year":"2009","journal-title":"Drug Saf."},{"key":"10.1016\/j.bbrc.2023.149130_bib148","series-title":"Targeting the Angiopoietin-Tie2 Pathway to Inhibit Early-Stage Cancer Metastasis","author":"Wu","year":"2017"},{"key":"10.1016\/j.bbrc.2023.149130_bib149","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1158\/1535-7163.MCT-09-0960","article-title":"Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer","volume":"9","author":"Hashimoto","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.bbrc.2023.149130_bib150","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1634\/theoncologist.2019-0291","article-title":"The McCAVE trial: vanucizumab plus mFOLFOX\u20106 versus bevacizumab plus mFOLFOX\u20106 in patients with previously untreated metastatic colorectal carcinoma (mCRC)","volume":"25","author":"Bendell","year":"2020","journal-title":"Oncol."},{"key":"10.1016\/j.bbrc.2023.149130_bib151","article-title":"Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients","volume":"8","author":"Machiels","year":"2020","journal-title":"J Immuno Ther Cancer"},{"key":"10.1016\/j.bbrc.2023.149130_bib152","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/leu.2013.38","article-title":"Phase Ia\/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies","volume":"27","author":"DeAngelo","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2023.149130_bib153","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/s10637-012-9921-8","article-title":"First-in-human phase 1\/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies","volume":"31","author":"Weiss","year":"2013","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.bbrc.2023.149130_bib154","doi-asserted-by":"crossref","first-page":"22611","DOI":"10.1073\/pnas.1016478108","article-title":"Chemical generation of bispecific antibodies","volume":"107","author":"Doppalapudi","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2023.149130_bib155","doi-asserted-by":"crossref","first-page":"6988","DOI":"10.1158\/0008-5472.CAN-16-0888","article-title":"Efficacy of co-targeting angiopoietin-2 and the VEGF pathway in the adjuvant postsurgical setting for early breast, colorectal, and renal cancers","volume":"76","author":"Wu","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2023.149130_bib156","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.canlet.2017.02.005","article-title":"The potential clinical promise of \u2018multimodality\u2019metronomic chemotherapy revealed by preclinical studies of metastatic disease","volume":"400","author":"Kerbel","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2023.149130_bib157","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.ccell.2014.11.005","article-title":"Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth","volume":"6","author":"Srivastava","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2023.149130_bib158","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-26620-1","article-title":"Structural insights into the clustering and activation of Tie2 receptor mediated by Tie2 agonistic antibody","volume":"12","author":"Jo","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2023.149130_bib159","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4688327","article-title":"Hybrid model for detection of cervical cancer using causal analysis and machine learning techniques","author":"Lilhore","year":"2022","journal-title":"Comput. Math. Methods Med."},{"key":"10.1016\/j.bbrc.2023.149130_bib160","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrc.2017.92","article-title":"Preclinical mouse solid tumour models: status quo, challenges and perspectives","volume":"12","author":"Gengenbacher","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2023.149130_bib161","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.11771.1","article-title":"The role of tumor microenvironment in resistance to anti-angiogenic therapy","volume":"7","author":"Ma","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.bbrc.2023.149130_bib162","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/sim.4780080404","article-title":"Surrogate endpoints in clinical trials: cancer","volume":"8","author":"Ellenberg","year":"1989","journal-title":"Stat. Med."},{"key":"10.1016\/j.bbrc.2023.149130_bib163","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.3390\/ijms22136995","article-title":"Macrophage polarization states in the tumor microenvironment","volume":"2","author":"Boutilier","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2023.149130_bib164","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrclinonc.2011.83","article-title":"Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?","volume":"8","author":"De Bock","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2023.149130_bib165","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1172\/JCI58832","article-title":"Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling","volume":"122","author":"Felcht","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrc.2023.149130_bib166","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/cam4.105","article-title":"Vessel co\u2010option in primary human tumors and metastases: an obstacle to effective anti\u2010angiogenic treatment?","volume":"2","author":"Donnem","year":"2013","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbrc.2023.149130_bib167","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrc3366","article-title":"Controlling escape from angiogenesis inhibitors","volume":"10","author":"Sennino","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2023.149130_bib168","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1039\/b614955c","article-title":"Controlling crystallization and its absence: proteins, colloids and patchy models","volume":"9","author":"Doye","year":"2007","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.bbrc.2023.149130_bib169","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc.2017.51","article-title":"Microenvironmental regulation of tumour angiogenesis","volume":"17","author":"De Palma","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2023.149130_bib170","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00401-018-1815-1","article-title":"Functional morphology of the blood\u2013brain barrier in health and disease","volume":"135","author":"Liebner","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbrc.2023.149130_bib171","first-page":"3370","article-title":"Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors","volume":"63","author":"Stoeltzing","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2023.149130_bib172","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc1093","article-title":"Tumorigenesis and the angiogenic switch","volume":"3","author":"Bergers","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2023.149130_bib173","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10456-014-9420-y","article-title":"Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions","volume":"17","author":"Vasudev","year":"2014","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bbrc.2023.149130_bib174","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ejca.2005.11.010","article-title":"Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases","volume":"242","author":"Chantrain","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbrc.2023.149130_bib175","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10456-007-9065-1","article-title":"Development of the retinal vasculature","volume":"10","author":"Fruttiger","year":"2007","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bbrc.2023.149130_bib176","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nn.4288","article-title":"Pericytes of the neurovascular unit: key functions and signaling pathways","volume":"19","author":"Sweeney","year":"2016","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bbrc.2023.149130_bib177","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/01.RES.0000182903.16652.d7","article-title":"Endothelial\/pericyte interactions","volume":"97","author":"Armulik","year":"2006","journal-title":"Circ. Res."},{"key":"10.1016\/j.bbrc.2023.149130_bib178","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.yexcr.2005.10.019","article-title":"Pericytes and vascular stability","volume":"312","author":"Von Tell","year":"2006","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bbrc.2023.149130_bib179","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015846","article-title":"A two-way communication between microglial cells and angiogenic sprouts regulates angiogenesis in aortic ring cultures","volume":"6","author":"Rymo","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2023.149130_bib180","first-page":"S10","article-title":"Angiogenesis and vasculogenesis in pregnancy. Eur. J. Obstet. Gynecol","volume":"110","author":"Zygmunt","year":"2003","journal-title":"Reprod. Biol."},{"key":"10.1016\/j.bbrc.2023.149130_bib181","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.cyto.2012.03.007","article-title":"Levels of angiopoietins 1 and 2 in induced sputum supernatant in patients with COPD","volume":"58","author":"Bessa","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.bbrc.2023.149130_bib182","series-title":"Endothelial Tie1 Regulates Tumor Angiogenesis, Vascular Abnormalization and Metastatic Dissemination","author":"La Porta","year":"2017"},{"key":"10.1016\/j.bbrc.2023.149130_bib183","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1177\/1947601911432334","article-title":"Molecular mechanisms of tumor angiogenesis","volume":"2","author":"Ziyad","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.bbrc.2023.149130_bib184","first-page":"455","article-title":"Vascular endothelial growth factor (VEGF)-key factor in normal and pathological angiogenesis","volume":"59","author":"Melincovici","year":"2018","journal-title":"Rom. J. Morphol. Embryol."},{"key":"10.1016\/j.bbrc.2023.149130_bib185","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.canlet.2012.08.018","article-title":"Angiopoietins in angiogenesis","volume":"328","author":"Fagiani","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2023.149130_bib186","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2008.01.003","article-title":"The blood-brain barrier in health and chronic neurodegenerative disorders","volume":"57","author":"Zlokovic","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.bbrc.2023.149130_bib187","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2353\/ajpath.2009.090391","article-title":"Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels","volume":"175","author":"Falc\u00f3n","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbrc.2023.149130_bib188","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1158\/0008-5472.CAN-04-1054","article-title":"Angiopoietin-3 inhibits pulmonary metastasis by inhibiting tumor angiogenesis","volume":"64","author":"Xu","year":"2004","journal-title":"Cancer Res."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X23012147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X23012147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:35:39Z","timestamp":1757766939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X23012147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":187,"alternative-id":["S0006291X23012147"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2023.149130","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic targeting of angiopoietins in tumor angiogenesis and cancer development","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2023.149130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"149130"}}